Contattaci Contact Us

Asthma and chronic obstructive pulmonary disease: which drugs?


Chronic respiratory diseases, in particular asthma and COPD (chronic obstructive pulmonary disease), are among the main causes of morbidity and mortality, and a growing trend is predicted for the coming years. The data provided by the World Health Organisation estimate that there are currently hundreds of millions of people suffer from chronic respiratory diseases:

  • approximately 300 million have asthma;
  • 80 million suffer from moderate to severe degree COPD;
  • another million suffer from the consequences of mild COPDs, allergic rhinitis and other chronic respiratory diseases.

What therapies are used with these patients?  Trying to answer this question will be the international symposium entitled “Pharmacology and therapeutics of bronchodilators” to be held from 19 to 21 October in Palazzo Brancaccio, Viale del Monte Oppio 7, Rome, organised by the Tor Vergata University of Rome and promoted by the Fondazione Internazionale Menarini.

Initially used to reduce the symptoms of respiratory disease, bronchodilators have benefited from scientific research and are now considered an essential element in the treatment of these diseases. During the symposium, Italian and international experts will describe the pharmacology of bronchodilators, discussing when to use a long-acting or fast-acting drug, at what dosage and how frequently, the relationship between bronchodilators and physical exercise, without forgetting the problem of doping in athletes, the use of these drugs in the elderly and the effects of bronchodilators on the cardiovascular system.



Mario Cazzola
University of Rome Tor Vergata

Paola Rogliani
University of Rome Tor Vergata

Reserved area